Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice

Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice

Aim. To evaluate the effect of PCSK9-targeted therapy on lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular diseases who have not achieved the target low-density lipoprotein cholesterol (LDL-C) level (statins at maximum tolerated doses and/or ezetimibe).Material and method...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. L. Kordzaya, E. Yu. Vasilyeva
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2025-01-01
Series:	Российский кардиологический журнал
Subjects:	lipoprotein(a) atherosclerotic cardiovascular diseases inclisiran
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/6177
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness of inclisiran lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2024-06-01)

Lipoprotein(a) as a risk factor for cardiovascular diseases - focus on ischemic stroke (a position paper)
by: Ia. B. Skiba, et al.
Published: (2024-06-01)

Observational study of inclisiran effectiveness in Moscow healthcare
by: A. I. Sapina, et al.
Published: (2023-12-01)

Lipid-lowering treatment in the improvement of outcomes in patients with atherosclerotic cardiovascular disease and diabetes mellitus: the role of PCSK9 inhibitors
by: G. R. Galstyan, et al.
Published: (2018-12-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

Lipoprotein(a) and the atherosclerotic burden – Should we wait for clinical trial evidence before taking action?
by: Isabella Fichtner, et al.
Published: (2024-12-01)

Prospects of Using PCSK9 Inhibitors for Acute Coronary Syndrome
by: A. M. Namitokov, et al.
Published: (2024-04-01)

Is it possible to regress atherosclerotic lesions with long-term treatment with lipoprotein apheresis?
by: Ulrich Julius, et al.
Published: (2024-10-01)

Small interfering RNA effect on lipoprotein(a): a systematic review
by: Omar Almaadawy, et al.
Published: (2025-05-01)

Discordance Between Very Low‐Density Lipoprotein Cholesterol and Low‐Density Lipoprotein Cholesterol Increases Cardiovascular Disease Risk in a Geographically Defined Cohort
by: Kristina E. Seehusen, et al.
Published: (2024-04-01)

Lipoprotein (a) integrates monocyte-mediated thrombosis and inflammation in atherosclerotic cardiovascular disease
by: Robert S. Rosenson, et al.
Published: (2025-06-01)

Lipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis
by: Chuanjie Wu, et al.
Published: (2025-07-01)

The Effects of Inclisiran on the Subclinical Inflammatory Markers of Atherosclerotic Cardiovascular Disease in Patients at High Cardiovascular Risk
by: Mateusz Maligłówka, et al.
Published: (2025-06-01)

Assessment of the Utilization of Lipoprotein (a) and its Relationship with Cardiovascular Outcomes: A Retrospective Cohort Study from a Public Hospital in New York City
by: Maisha Maliha, et al.
Published: (2025-01-01)

The heterogeneity of lipoproteins and their role in the development of cardiovascular diseases
by: E. A. Utkina, et al.
Published: (2019-06-01)

PCSK9 Antagonists: Clinical Efficacy and Main Trends in the Development of New Medicines
by: A. A. Nekipelova, et al.
Published: (2023-09-01)

Lipoprotein(a) as underestimated cardiovascular risk factor in Russia. Time to introduce into clinical practice
by: O. I. Afanasyeva, et al.
Published: (2024-10-01)

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and cerebral atherosclerotic stenosis: a retrospective study
by: Yating Han, et al.
Published: (2025-04-01)

Role of Lipoprotein(a) in Atherosclerotic Cardiovascular Disease in South Asian Individuals
by: Darshan Patel, et al.
Published: (2025-07-01)

Temporal trends in lipoprotein(a) testing among United States veterans from 2014 to 2023
by: Sofia E. Gomez, et al.
Published: (2024-12-01)

Elevated levels of lipoprotein(a) and low-density lipoprotein cholesterol in familial hypercholesterolemia patients: is dual primary prevention already in sight?
by: Alpo Vuorio, et al.
Published: (2025-07-01)

Inhibitors in the Management of Patients with Atherosclerotic Cardiovascular Diseases: Guidelines and Reimbursement Issues
by: M. V. Zhuravleva, et al.
Published: (2020-09-01)

Predictive value of serum lipoprotein-associated phospholipase A2 for coronary atherosclerotic heart disease in elderly patients with hypertension
by: Zhang Mimi, et al.
Published: (2025-03-01)

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis
by: Shengxuan Zhang, et al.
Published: (2024-11-01)

Circulating Endothelial Progenitor Cells in Patients with Established Cardiovascular Disease Treated with PCSK9 Monoclonal Antibodies
by: Chen Gurevitz, et al.
Published: (2024-12-01)

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01)

DETECTION OF MODIFIED LIPOPROTEINS IN ATHEROSCLEROTIC LESIONS OF HUMAN AORTA
by: P. V. Pigarevsky, et al.
Published: (2014-07-01)

Relationship of obesity, low-density lipoprotein cholesterol and myocardial perfusion in patients with risk factors and without atherosclerotic cardiovascular diseases
by: V. B. Sergienko, et al.
Published: (2021-03-01)

Obesity and Atherosclerotic Cardiovascular Disease: A Review of Social and Biobehavioral Pathways
by: Izza Shahid, et al.
Published: (2025-02-01)

Fibrinogen-to-albumin ratio predicts mortality in patients with diabetes mellitus and atherosclerotic cardiovascular disease
by: Haixu Yu, et al.
Published: (2025-05-01)

Association Between Visual Acuity and Incident Atherosclerotic Cardiovascular Disease: A Longitudinal Test of Mediators
by: Zijing Du, et al.
Published: (2025-02-01)

Atherosclerotic plaque in carotid arteries as a risk marker for cardiovascular events risk in middle aged population
by: A. I. Ershova, et al.
Published: (2018-08-01)

Efficacy and safety of lipid-lowering therapies in combination with or without statin to reduce the cardiovascular risk: A systematic review of randomised controlled trials
by: Gabriella Iannuzzo, et al.
Published: (2024-12-01)

Lipoprotein(a), atherosclerosis and cardiovascular risk
by: E. A. Polyakova, et al.
Published: (2024-12-01)

Lipoprotein(a) and cardiovascular disease: Evidence, recommendations and emerging therapies
by: Wong Nathan D.
Published: (2025-01-01)

First Russian experience of treating dyslipidemia with siRNA drugs in patients after heart transplantation
by: M. A. Simonenko, et al.
Published: (2024-02-01)

LIPOPROTEIN(A) MEANING AS AN ADDITIONAL MARKER OF CARDIOVASCULAR RISK IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
by: V. A. Korneva, et al.
Published: (2016-06-01)

Safety and Efficacy of Inclisiran in Hyperlipidemia: An Updated Meta‐Analysis of Randomised Controlled Trials
by: Jawad Basit, et al.
Published: (2025-03-01)

Atherosclerotic Cardiovascular Diseases in Middle Delta of Egypt: A Systematic Analysis of Risk Factors Associated with the Rising Burden of the Disease
by: Mohamed Khalfallah, et al.
Published: (2025-02-01)

Predictors of lipoprotein(a) variability in clinical practice and their impact on cardiovascular risk
by: Hyung Joon Joo, et al.
Published: (2025-07-01)